Fugate, J.E. and Rabinstein, A.A. (2015) Posterior Reversible Encephalopathy Syndrome: Clinical and Radiological Manifestations, Pathophysiology, and Outstanding Questions. The Lancet Neurology, 14, 914-925.
https://doi.org/10.1016/s1474-4422(15)00111-8

has been cited by the following article:

• TITLE: Posterior Reversible Encephalopathy Syndrome (PRES) Complicated by Subarachnoid Hemorrhage Induced by Chemotherapy: A Rare Case and Literature Review

  AUTHORS: Samia El Hakym, Hafssa El Hilali, Chaymae Chbihi, Sara Nejjari, Diango Keita, Imane El Ouafki, Lamyae Amaadour, Karima Oualla, Zineb Benbrahim, Nawfel Mellas

  KEYWORDS: Posterior Reversible Encephalopathy Syndrome (PRES), Oxaliplatin, FOLFOX, Subarachnoid Hemorrhage, Chemotherapy, Neurological Complications

  JOURNAL NAME: Journal of Cancer Therapy, Vol.17 No.1, December 31, 2025

  ABSTRACT: Posterior Reversible Encephalopathy Syndrome (PRES) is a rare neurological entity characterized by vasogenic cerebral edema, often triggered by hypertension, renal failure, preeclampsia, certain immunosuppressive drugs, or chemotherapeutic agents. We report the case of a 68-year-old woman with multifocal metastatic intrahepatic cholangiocarcinoma who developed PRES complicated by subarachnoid hemorrhage following the administration of the third cycle of FOLFOX chemotherapy. The clinical picture included headaches, visual disturbances, and recurrent generalized tonic-clonic seizures. Brain magnetic resonance imaging (MRI) confirmed the diagnosis by showing bilateral and symmetrical T2/FLAIR hyperintensities predominantly in the parieto-occipital regions, consistent with vasogenic edema, associated with minimal leptomeningeal bleeding signs. Management consisted of immediate discontinuation of chemotherapy, strict blood pressure control, and anticonvulsant therapy, leading to a rapidly favorable outcome. This case highlights the rarity of oxaliplatin as a causative agent and the importance of heightened clinical vigilance for any acute neurological symptom in a patient undergoing chemotherapy, to enable early management and improve prognosis.